There are currently few effective treatments available for advanced or metastatic uveal melanoma, including surgery to remove the cancer, radiotherapy or chemotherapy. IMCgp100 is a drug under development that would enable the body’s own immune system to recognise and specifically target and kill cancer cells. IMCgp100 is given by intravenous infusion and is currently being studied in patients with advanced/ metastatic uveal melanoma. It will offer a new treatment option if licenced.
Axitinib is a tablet taken twice per day which works by interfering with the growth of the blood vessels which supply blood to the cancer cells. In other types of cancer, Axitinib has been seen to slow down the growth and stop cancers from spreading to other parts of the body. Axitinib is already available to treat RCC which has already advanced or spread, however if axitinib is licenced for use after surgery to prevent the growth and spread of further tumours (as an adjuvant therapy), this may prevent the progression and spread of RCC to other sites of the body.